SCHEMBL2685002

SCHEMBL2685002

Cc1cc(-c2cc(Cl)cc(NC(=O)[C@@H](N)Cc3ccccc3)c2)ccn1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPR142 Q7Z601 3/20 0.51
▸ PSEN1 P49768 6/20 0.48
▸ PSEN2 P49810 6/20 0.48
▸ APH1B Q8WW43 6/20 0.48
▸ NCSTN Q92542 6/20 0.48
▸ APH1A Q96BI3 6/20 0.48
▸ PSENEN Q9NZ42 6/20 0.48
▸ CIT O14578 1/20 0.47
▸ WNT3A P56704 5/20 0.46
▸ RORA P35398 1/20 0.45
▸ NR2E1 Q9Y466 1/20 0.45
▸ AKT1 P31749 1/20 0.45
▸ ROCK2 O75116 1/20 0.43
▸ ROCK1 Q13464 1/20 0.43
▸ FTO Q9C0B1 1/20 0.42
▸ PORCN Q9H237 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2684777 0.87 GPR142 (0.57) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2686200 0.82 GPR142 (0.46) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2686202 0.81 GPR142 (0.65) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2685260 0.79 GPR142 (0.53) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2685594 0.77 HDAC8 (0.45) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2685599 0.77 HDAC8 (0.45) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2683696 0.77 GPR142 (0.57) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2686723 0.76 GPR142 (0.47) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2686712 0.76 GPR142 (0.47) GPR142PSEN1PSEN2APH1BNCSTN
SCHEMBL2684336 0.75 GPR142 (0.53) GPR142PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885PSEN1 703/4885PSEN2 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback